CAMBRIDGE, Mass.--()--Agios Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the Cowen and Company 33rd Annual Health Care Conference on Monday, March 4, 2013 at 9:30AM EST at the Boston Marriott Copley Place.
Dr. Schenkein is expected to discuss the company’s portfolio of cancer metabolism therapeutics, its expansion into targeting inborn errors of metabolism, and the assets and capabilities that position Agios as a leader in dysregulated metabolism.
About Agios Pharmaceuticals, Inc.
Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.